Three consecutive years of gains + all-time highs! Can the US stock market continue its bull run in
On the last trading day of 2025, the U.S. stock market concluded quietly with minor declines in the three major indexes: $Dow Jones Industrial Average (.DJI.US)$ Falling by 0.63%, $Nasdaq Composite Index (.IXIC.US)$ Falling by 0.76%, $S&P 500 Index (.SPX.US)$ with a decline of 0.74%. The overall market trading atmosphere appeared relatively subdued, with investors generally adopting a wait-and-see attitude, awaiting new market catalysts to emerge in 2026. Despite closing lower on the last day, US stocks still performed strongly throughout 2025, with the three major indices recording double-digit annual gains for the third consecutive year.
Cathie Wood, head of ARK Invest, did not choose to rest on the last trading day of 2025 but continued to adjust the holdings of her funds.
According to the portfolio data released by ARK Invest, 'Wood' executed multiple buy and sell operations on December 31st. The ARK team maintained its consistent high-frequency trading style, persisting in optimizing the investment portfolio structure even during the year-end period when market liquidity was lower.
A series of portfolio adjustments demonstrated that fund managers had clear expectations regarding the performance of specific sectors in 2026. ARK Invest took advantage of the market pullback to withdraw funds from some profitable positions and reallocate them into areas deemed to have higher growth potential.

Detailed Explanation of Increased Positions: Significant Focus on Gene Editing and Biotechnology
Observing ARK Invest's buy list on December 31st, the flow of funds showed a very evident industry concentration, with biotechnology and gene editing becoming the core focus of increased positions.
ARK added 90,800 more shares on that day $Intellia Therapeutics (NTLA.US)$ in a biotech company specializing in CRISPR/Cas9 gene-editing therapies.
Following closely is $Beam Therapeutics (BEAM.US)$ , with ARK adding 90,100 shares. This company is known for its precise single-base editing technology.
In addition to these two gene-editing giants, ARK also continued to purchase 32,700 shares of $Twist Bioscience (TWST.US)$ , a synthetic biology company that provides high-quality synthetic DNA.
Ms. Wood concentrated substantial funds into these cutting-edge life sciences companies at year-end, indicating ARK Invest's strong confidence in gene-editing technology achieving commercial breakthroughs or valuation recovery by 2026.
Analysis of Reduction List: Tactical Adjustments and Resource Reallocation
Regarding the selling list, ARK Invest’s actions primarily reflect fine-tuning and balancing of current holdings.
Roku Inc (ROKU), a streaming hardware and platform company, has been reduced in holdings. As a long-term overweight position for ARK, this reduction appears to be more of a risk management measure to control the weight of a single holding.
$Ionis Pharmaceuticals (IONS.US)$: Reduced by 8,843 shares
Ionis Pharmaceuticals (IONS), an RNA-targeted drug development company, sold 8,843 shares, representing a technical reduction at a high position.
$Shopify (SHOP.US)$: Reduced by 2,222 shares
$Rocket Lab (RKLB.US)$: Reduced by 1,481 shares
From the magnitude of the reductions, the sell-off volumes for e-commerce platform Shopify and space exploration company Rocket Lab were relatively small. Such operations are typically part of routine tactical reductions or fund reallocations.
ARK Invest partially liquidated these highly liquid tech stocks, providing funding support for large-scale purchases in the gene-editing sector, completing a partial rotation of the portfolio from internet technology to biotechnology.

Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Comments
to post a comment
104
27
